Side-by-side comparison: effects, dosing ranges, side effects, regulatory status, and reconstitution.
Peptide A
Healing & Recovery
Gastric pentadecapeptide with broad tissue-healing properties.
Peptide B
Healing & Recovery
The 7-amino-acid active fragment of TB-500, isolated for cell-migration effects.
Typical vial
5 mg
Typical dose
250-500 mcg
Half-life
~4 hours (estimated from animal pharmacokinetic data)
FDA status
Not FDA approved for human use. FDA issued a warning letter …
Typical vial
10 mg
Typical dose
2000-5000 mcg
Half-life
Estimated minutes to a few hours (much shorter than full TB-500 due to lack of N/C-terminal protection)
FDA status
Not FDA approved for any human or veterinary use. No clinica…
BPC-157 effects
TB-500 Fragment 17-23 effects
BPC-157 side effects
TB-500 Fragment 17-23 side effects
BPC-157 dosing ranges
General tissue repair
250-500 mcg · Once or twice daily · 4-6 weeks
Gut healing
250-500 mcg · Twice daily (oral or SubQ) · 4-8 weeks
Acute injury recovery
500 mcg · Twice daily near injury site · 2-4 weeks
TB-500 Fragment 17-23 dosing ranges
Injury recovery (extrapolated)
2-5 mg · Twice weekly SubQ · 4-6 weeks
Tendon/ligament support (extrapolated)
2-5 mg · Twice weekly SubQ · 4-8 weeks
Loading phase (anecdotal)
5 mg · Twice weekly for 2-3 weeks · Then maintenance
BPC-157: Gastric pentadecapeptide with broad tissue-healing properties. Typical dose 250-500 mcg. TB-500 Fragment 17-23: The 7-amino-acid active fragment of TB-500, isolated for cell-migration effects. Typical dose 2000-5000 mcg. Both fall under the Healing & Recovery category.
Stacking BPC-157 with TB-500 Fragment 17-23 is a protocol-design question best raised with a clinician — it depends on your goal, current bloodwork, and whether both peptides target overlapping mechanisms. Both peptides should be tracked independently with separate injection sites and timing. PinnyPeptide supports multi-peptide stacks with automatic injection site rotation.
BPC-157 is typically dosed: Once or twice daily for General tissue repair; Twice daily (oral or SubQ) for Gut healing; Twice daily near injury site for Acute injury recovery. TB-500 Fragment 17-23 is typically dosed: Twice weekly SubQ for Injury recovery (extrapolated); Twice weekly SubQ for Tendon/ligament support (extrapolated); Twice weekly for 2-3 weeks for Loading phase (anecdotal).
BPC-157: Not FDA approved for human use. FDA issued a warning letter in 2024 regarding compounded BPC-157 products. TB-500 Fragment 17-23: Not FDA approved for any human or veterinary use. No clinical trials have been conducted on this specific fragment.
Log doses, automate injection site rotation, and never lose track of where you last pinned. Free forever.
Get Started Free